Scroll Back to Top
Contact Us
Podcast

Diabetes Dialogues

Episode 1: Cracking the T1D cure code: From breakthrough science to breakthrough access

This episode brings together Dr. Friedrich Mittermayer and Dr. Esther Latres PhD, VP of Research, to discuss the exciting cures for T1D, and the challenges those clinical trials face.

This podcast episode explores the urgent realities and untapped opportunities in adult T1D diagnosis and treatment. From the heartbreak of misdiagnosis to the promise of cell and gene therapies, we spotlight the real-world journeys that shape clinical trial access and outcomes. You’ll hear how delayed diagnoses push young adults beyond critical trial windows, why older patients are often overlooked, and how new tools—from EMR pilots to genetic rescores—are helping us find the right patients, faster.

With insights from Breakthrough T1D, we rally around a shared vision: a world without T1D. Because the future of diabetes care isn’t just about innovation—it’s about inclusion.

  • Host: Dr. Friedrich Mittermayer, Sr. Medical Director for Endocrinology, Fortrea
  • Participants: Dr. Esther Latres PhD, VP of Research at Breakthrough T1D

References:

  1. Brixner, D., Beyene, T. J., Venkataraman, M., Teng, C.-C., Chen, H.-Y. P., Tan, H., Wilson, L., Cagle, A., & Malone, D. C. (2025). Diagnostic delay in people with Type 1 diabetes and a prior Type 2 diabetes diagnosis—A U.S. managed care population. Diabetes, 74(Supplement_1), 1080–P. https://doi.org/10.2337/db25-1080-P
  2. Breakthrough T1D. (2025, June 24). ADA 2025 Recap: Improving Lives. https://www.breakthrought1d.org/news-and-updates/ada-2025-recap-improving-lives/
  3. Breakthrough T1D. (2025, January 7). Cell therapy first: Transplanted islets working without immunosuppressives. https://www.breakthrought1d.org/news-and-updates/cell-therapy-first-transplanted-islets-working-without-immunosuppressives/
  4. Breakthrough T1D & IQVIA. (2025). Predicting misdiagnosed adult-onset Type 1 diabetes using machine learning [Case study]. IQVIA. https://www.iqvia.com/-/media/iqvia/pdfs/us/case-study/2025/iqvia-breakthrough-t1d-case-study-2025.pdf
  5. Herold, K. C., Bundy, B. N., Long, S. A., et al. (2025). Early intervention in pediatric Type 1 diabetes: C-peptide preservation within the first 100 days. Journal of Clinical Medicine, 14(7), 3962. https://pmc.ncbi.nlm.nih.gov/articles/PMC12156930/pdf/jcm-14-03962.pdf
  6. Jeyam, A., Colhoun, H., McGurnaghan, S., et al. (2021). Clinical impact of residual C-peptide secretion in type 1 diabetes on glycemia and microvascular complications. Diabetes Care, 44(2), 390–398. https://doi.org/10.2337/dc20-0567
  7. JDRF. (2025). Disease-Modifying Therapies Research. https://www.jdrf.org/disease-modifying-therapies/research-d-m-t/
  8. Rickels, M. R., Ballou, C. M., Foster, N. C., Alejandro, R., Baidal, D. A., Bellin, M. D., ... & Payne, E. H. (2025). Islet transplantation versus standard of care for type 1 diabetes complicated by severe hypoglycemia. Diabetes Care, 48(5), 737–744. https://doi.org/10.2337/dc24-1915
  9. Rosemont Pharmaceuticals Ltd. (2023). Verapamil 40mg/5ml Oral Solution: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/files/pil.13118.pdf

Episode 2: The critical first 100 days for pediatric Type 1 diabetes patients

This episode brings together Mala Puri, Senior Medical Director at Fortrea and Dr. Sanjoy Dutta PhD Chief Scientific Officer to discuss the unique challenges faced by pediatric populations in Type 1 diabetes clinical trials.

We explore the specific needs and barriers for children and their families, and the role of advocacy and research groups in supporting them. The conversation highlights practical examples of support programs and tools that can help pediatric patients participate in clinical trials, ensuring their voices are heard and their needs are met.

  • Host: Dr. Mala Puri, Senior Medical Director at Fortrea
  • Participants: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1D

References:

  1. Albanese-O’Neill A, Phillip M, Achenbach P, et al. Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care. 2024;47(8):1276–1298. Accessed Aug. 18, 2025.
  2. Besser REJ, Bell KJ, Couper JJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of Type 1 Diabetes in Children and Adolescents. Pediatr Diabetes. 2022. Accessed August 18, 2025.
  3. Couper J. Preserving Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes. JAMA. 2023;329(12):978–979. Accessed Aug. 18, 2025.
  4. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–983. Accessed Aug. 18, 2025.
  5. Gubitosi-Klug RA, Braffett BH, Hitt S, et al. Residual β Cell Function in Long-Term Type 1 Diabetes Associates With Reduced Incidence of Hypoglycemia. J Clin Invest. 2021;131(3):e143011. Accessed Aug. 18, 2025.
  6. Insel RA, Dunne JL, Atkinson MA, et al. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–1974. Accessed Aug. 18, 2025.
  7. JDRF. JDRF Celebrates FDA Approval of Artificial Pancreas System. Oct. 20, 2016. Accessed Aug. 18, 2025.
  8. JDRF. At-Home Overnight Artificial Pancreas Trial Reveals Health and Lifestyle Benefits for Adolescents. May 5, 2014. Accessed Aug. 18, 2025.
  9. JDRF. JDRF Research Progress Report Fall 2014. Accessed Aug. 18, 2025.
  10. Karges B, Prinz N, Placzek K, et al. A Comparison of Familial and Sporadic Type 1 Diabetes Among Young Patients. Diabetes Care. 2021;44(5):1116–1124. Accessed Aug. 18, 2025.
  11. Krischer JP, Lynch KF, Schatz DA, et al. The 6-Year Incidence of Diabetes-Associated Autoantibodies in Genetically At-Risk Children: The TEDDY Study. Diabetologia. 2015;58(5):980–987. Accessed Aug. 18, 2025.
  12. Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes. 2014;63(2):739–748. Accessed Aug. 18, 2025.
  13. Latres E, Greenbaum CJ, Oyaski ML, et al. Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes. 2024;73(6):823–833. Accessed Aug. 18, 2025.
  14. Lundkvist P, Grönberg A, Carlsson PO, et al. Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes. BMJ Open Diabetes Res Care. 2024;12(1):e003924. Accessed Aug. 18, 2025.
  15. Martin S, Herder C, Schloot NC, et al. Residual Beta Cell Function in Newly Diagnosed Type 1 Diabetes after Treatment with Atorvastatin: The Randomized DIATOR Trial. PLoS One. 2011;6(3):e17554. Accessed Aug. 18, 2025.
  16. Provention Bio, Inc. TZIELD (teplizumab-mzwv) injection, for intravenous use. Prescribing Information. U.S. Food and Drug Administration. Rev. Nov. 2022. Accessed Aug. 18, 2025.
  17. Templeman E, Ferrat LA, Thomas N, et al. Natural History of Type 1 Diabetes (T1D)—Contrasting Adult vs Pediatric At-Risk Populations. Diabetes. 2024;73(Suppl 1):1443-P. Accessed Aug. 18, 2025.
  18. Vehik K, Lynch KF, Schatz DA, et al. Reversion of β-cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes Care. 2016;39(9):1535–1542. Accessed Aug. 18, 2025.
  19. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473–2479. Accessed Aug. 18, 2025.

Episode 3: The human side of pediatric Type 1 diabetes

This episode brings together Mala Puri, Senior Medical Director at Fortrea and Dr. Sanjoy Dutta PhD, Chief Scientific Officer to discuss the unique challenges faced by pediatric populations in Type 1 diabetes clinical trials.

In our previous episode, we explored the scientific foundation behind treating T1D as an autoimmune disease and the critical importance of those first 100 days after diagnosis. In this episode, we shift our focus to the human side of the equation. We'll tackle the real-world hurdles families face when navigating a new T1D diagnosis - from emotional overwhelm to information overload. More importantly, we'll discuss how we can design clinical trials that work for families, not against them, and explore the transformative power of true partnerships between sponsors, CROs, and patient advocacy groups.

  • Host: Dr. Mala Puri, Senior Medical Director at Fortrea
  • Participants: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1D

References:

  1. MiniMed 780g, Tandem t:slim X2 with Control-IQ technology, Omnipod 5, CamAPS FX, Diabeloop DBLG1, Medtrum A6 Touch Care System, YpsoPump with CamAPS FX, Dana-I with CamAPS, Beta Bionics iLet Bionic Pancreas
  2. Provention Bio, Inc. TZIELD (teplizumab-mzwv) injection, for intravenous use. Prescribing Information. U.S. Food and Drug Administration. Rev. Nov. 2022. Accessed Aug. 18, 2025.

Connect with us

We’ve been driving innovation with our tailored clinical solutions for 30+ years. Let’s connect.

* denotes required fields

Service Interest(s)
(Word, PDF, PPT, Excel, Image)
One file only.
60 MB limit.
Allowed types: gif, jpg, jpeg, png, bmp, txt, rtf, html, pdf, doc, docx, ppt, pptx, xls, xlsx, xml.

I agree to be contacted about products and services and receive other communications from Fortrea Inc. Please review Fortrea's Privacy Policy for further information. By clicking submit below, you consent to allow Fortrea Inc to store and process the personal information submitted above to provide you the content requested.

Explore Careers at Fortrea

Join our Site Network
Submit a Site Payment Inquiry

Learn more about participating in a Fortrea Clinical Trial